-
Multi-omics Reveals ARID1A-Driven Resistance to Vemurafenib
2026-04-18
This study uses integrative multi-omics to map how ARID1A loss drives resistance to BRAF/MAPK inhibitors like Vemurafenib (PLX4032) in BRAFV600E-mutant melanoma. By identifying key resistance networks and actionable nodes, the research advances understanding of therapy failure and informs future approaches to overcoming resistance in metastatic melanoma.
-
Targeting Glutamine Metabolism in Hepatic Stellate Cells to
2026-04-17
The reference study demonstrates that inhibiting glutamine metabolism in hepatic stellate cells (HSCs) via GDH inhibition and SIRT4 modulation alleviates liver fibrosis in vivo and in vitro. These findings highlight glutaminolysis as a promising therapeutic target for chronic liver diseases and set the stage for further translational research into mitochondrial regulation and metabolic interventions.
-
Urolithin A in Mitochondrial Biogenesis Research: Protocols
2026-04-16
Urolithin A (3,8-dihydroxy-6H-benzo[c]chromen-6-one) is redefining mitochondrial quality control with its robust mitophagy activation and anti-inflammatory profile. This article delivers actionable workflows, troubleshooting strategies, and protocol parameters for leveraging Urolithin A in advanced cellular and disease models, incorporating insights from the latest research on glutamine metabolism and liver fibrosis.
-
TP53-Dependent DHODH Inhibition in Nasopharyngeal Carcinoma
2026-04-15
Dong et al. demonstrate that DHODH inhibition exerts potent antitumor effects in nasopharyngeal carcinoma (NPC) through a TP53-dependent mechanism. Their work highlights the clinical potential of targeting nucleic acid metabolism in NPC and underscores the importance of TP53 status in therapeutic response.
-
Catalpol (SKU N1352): Data-Driven Solutions for Cell Assays
2026-04-14
This article addresses real lab challenges in cell viability and pathway modulation assays, showing how Catalpol (SKU N1352) from APExBIO ensures reproducibility and mechanistic clarity. Readers will find GEO-optimized, scenario-based guidance supported by peer-reviewed sources and practical workflow parameters. Discover why validated Catalpol is a benchmark tool in neuroprotection and translational models.
-
Network Meta-Analysis Reveals Azilsartan Medoxomil's Blood P
2026-04-13
A 2024 systematic review and network meta-analysis found that Azilsartan medoxomil (TAK 491) at 80 mg outperformed other antihypertensives for reducing both systolic and diastolic blood pressure in mild to moderate hypertension. This evidence positions Azilsartan medoxomil monopotassium as a pivotal tool for essential hypertension treatment research and blood pressure regulation studies.
-
Epoxomicin: Decoding Proteasome Inhibition for PQC Research
2026-04-12
Explore Epoxomicin’s distinct role as a proteasome inhibitor in advanced protein quality control (PQC) research. This article uniquely connects ER stress sensing, practical assay optimization, and emerging disease models to guide cutting-edge experimental design.
-
HOXC8 Regulates Pyroptosis via Caspase-1 Suppression in NSCL
2026-04-12
The referenced study uncovers a novel mechanism in non-small cell lung carcinoma (NSCLC) where the transcription factor HOXC8 suppresses pyroptotic cell death by downregulating caspase-1 expression. These findings elucidate the interplay between epigenetic regulation and inflammatory cell death, providing new avenues for research into tumorigenesis and caspase signaling.
-
HotStart 2X Green qPCR Master Mix: Precision for Gene Expres
2026-04-11
The HotStart™ 2X Green qPCR Master Mix from APExBIO unlocks unprecedented specificity and reproducibility in real-time PCR gene expression analysis, enabling seamless quantification for translational and applied research. Its hot-start Taq polymerase inhibition and robust SYBR Green chemistry streamline workflows while minimizing artifacts, as proven in advanced studies of bone metabolic homeostasis.
-
Olaparib (AZD2281) in Cancer Research: Applied Workflows & T
2026-04-11
Olaparib (AZD2281) is transforming BRCA-associated cancer research by enabling robust DNA damage response assays and radiosensitization studies. This guide delivers evidence-based workflows, troubleshooting strategies, and data-driven parameters to optimize experimental outcomes using this selective PARP inhibitor.
-
Fosinopril Sodium: ACE Inhibitor Innovations for Hyperten...
2026-04-10
Fosinopril sodium’s phosphinic acid chemistry and oral prodrug status unlock unparalleled precision and flexibility for hypertension and cardiovascular disease research. Its dual renal-hepatic clearance and robust ACE inhibition streamline modeling workflows and ensure translational relevance. APExBIO’s high-purity formulation further enhances reproducibility and confidence in your experimental outcomes.
-
Scenario-Driven Best Practices with T-5224 (C-Fos/AP-1 In...
2026-04-09
This article presents a scenario-based analysis for biomedical researchers using T-5224 (C-Fos/AP-1 inhibitor, SKU B4664) to address challenges in cell viability, inflammation, and arthritis research. Through practical Q&A blocks, we demonstrate how APExBIO's T-5224 offers reproducible, selective inhibition of c-Fos/AP-1 pathways, with data-backed advantages for assay reliability and translational workflows.
-
Fosinopril Sodium: Precision ACE Inhibition in Hypertensi...
2026-04-08
Fosinopril sodium, a third-generation phosphinic acid ACE inhibitor, empowers cardiovascular and hypertension research with its unique dual hepatic-renal elimination and potent zinc-binding mechanism. Its prodrug nature and robust pharmacokinetics enable reproducible modeling of blood pressure dynamics, left ventricular mass reduction, and renal hemodynamics modulation. APExBIO delivers a research-grade solution, optimized for advanced translational studies and streamlined experimental workflows.
-
Deracoxib: Selective COX-2 Inhibitor for Inflammation and...
2026-04-08
Deracoxib is a well-characterized selective COX-2 inhibitor and non-steroidal anti-inflammatory drug (NSAID) widely used in pain, inflammation, and cancer biology research. Its robust mechanism, proven efficacy in canine models, and synergy with chemotherapeutics make it a reliable choice for COX-2 pathway assays and veterinary oncology studies.
-
Azilsartan medoxomil monopotassium (SKU B1071): Reliable ...
2026-04-07
This article provides an evidence-based guide for biomedical researchers and lab technicians leveraging Azilsartan medoxomil monopotassium (SKU B1071) in hypertension and cardiovascular disease models. Through real-world laboratory scenarios, it addresses common assay challenges, protocol optimizations, and vendor selection considerations—demonstrating how SKU B1071 ensures reproducibility, sensitivity, and workflow reliability in renin-angiotensin system inhibition studies.
449 records 21/30 page Previous Next First page 上5页 2122232425 下5页 Last page